|
|
Article: Avidia's Third Round: $44M For Avimer-Based Pipeline.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Preparing to enter the clinic with its first drug candidate this summer, Avidia Inc. closed its largest financing to date, raising $43.8 million in a Series C round.
The funding is expected to provide the company with financial flexibility as it moves its two lead products, both derived from its avimer drug discovery engine, through proof-of-concept development, said Peter Van Vlasselaer, CEO of the Mountain View, Calif.-based company.
Though the company originally hadn't planned to raise money until later this year - its Series B round brought in $28 million only a year ago - it couldn't resist taking advantage of investor ...
Related newspaper, magazine, and journal articles:
|
|
Article: Avidia, Inc. Raises $28.5 Million in Series B Financing.
PR Newswire;
May 5, 2005 ;
700+ words
... ... specific biologic function. Avidia's products have a tailored ... immunogenicity and manufacturing cost. Avidia's product format is broadly ... technology", said Dr. Peter Van Vlasselaer, Chief Executive Officer of Avidia. "Our lead candidate, which ...
|
|